Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2019

Open Access 01-12-2019 | Breast Cancer | Research article

In vitro and in vivo effects of traditional Chinese medicine formula T33 in human breast cancer cells

Authors: Yu-Te Liu, Chao-Hsiang Hsiao, Bor-Show Tzang, Tsai-Ching Hsu

Published in: BMC Complementary Medicine and Therapies | Issue 1/2019

Login to get access

Abstract

Background

Breast cancer is the leading cause of cancer-related death in women worldwide. Although traditional Chinese medicine (TCM) is commonly used by patients with breast cancer, little is known about TCM prescriptions for breast cancer. This study investigated the effects of a new TCM formula, T33, comprising Radix Kansui, Rheum rhabarbarum, Paeonia lactiflora, Jiangbanxia, and Zhigancao on breast cancer cells in vitro and in vivo.

Methods

To evaluate the effects of T33 on human breast cancer, HMEpiC, MDA-MB231 and MCF-7 cells were treated with different concentrations of T33 and then analyzed using MTT and Transwell migration assays. To elucidate the involvement of autophagy in the T33-induced death of MDA-MB231 and MCF-7 cells, immunofluorescence staining with LC3-II-specific antibodies was performed. Tumor xenografts were generated by subcutaneously injecting either MDA-MB231 or MCF-7 cells into BALB/c nude mice to determine the effects of T33 on these cell lines in vivo.

Results

The experimental results revealed that 0.1 mg/mL, 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33 significantly inhibited the proliferation and invasion of MDA-MB231 and MCF-7 cells. Moreover, significant autophagy was observed in MDA-MB231 and MCF-7 cells in the presence of 2.5 mg/mL, 5 mg/mL and 10 mg/mL T33. An animal study further revealed that both low (200 mg/kg) and high (600 mg/kg) doses of T33 inhibited the proliferation of xenografted breast cancer cells in BALB/c nude mice.

Conclusion

These findings demonstrate for the first time that T33 has potential in the treatment of breast cancer owing to its antiproliferative effects and induction of autophagy.
Literature
1.
go back to reference Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef
2.
go back to reference Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. Int J Cancer. 2016;139:2436–46.CrossRef Fidler MM, Soerjomataram I, Bray F. A global view on cancer incidence and national levels of the human development index. Int J Cancer. 2016;139:2436–46.CrossRef
3.
4.
go back to reference Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol. 2012;13:790–801.CrossRef Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol. 2012;13:790–801.CrossRef
5.
go back to reference Lukaszewicz K, Wtorek J, Bujnowski A, Skokowski J. Monitoring of breast tissue thermo-ablation by means of impedance measurements. J Phys Conf Ser. 2010;224:012136.CrossRef Lukaszewicz K, Wtorek J, Bujnowski A, Skokowski J. Monitoring of breast tissue thermo-ablation by means of impedance measurements. J Phys Conf Ser. 2010;224:012136.CrossRef
6.
go back to reference Dickler A, Ivanov O, Francescatti D. Intraoperative radiation therapy in the treatment of early-stage breast cancer utilizing xoft axxent electronic brachytherapy. World J Surg Oncol. 2009;7:24–9.CrossRef Dickler A, Ivanov O, Francescatti D. Intraoperative radiation therapy in the treatment of early-stage breast cancer utilizing xoft axxent electronic brachytherapy. World J Surg Oncol. 2009;7:24–9.CrossRef
7.
go back to reference Kruzliak P, Stefanicka P, Büsselberg D, Abotaleb M, Kubatka P, Caprnda M, Varghese E, Zolakova B, Zubor P, Opatrilova R. Chemotherapeutic agents for the treatment of metastatic breast cancer: an update. Biomed Pharmacother. 2018;101:458–77.CrossRef Kruzliak P, Stefanicka P, Büsselberg D, Abotaleb M, Kubatka P, Caprnda M, Varghese E, Zolakova B, Zubor P, Opatrilova R. Chemotherapeutic agents for the treatment of metastatic breast cancer: an update. Biomed Pharmacother. 2018;101:458–77.CrossRef
8.
go back to reference Sun Y. The role of Chinese medicine in clinical oncology. Chin J Integr Med. 2014;20:3–10.CrossRef Sun Y. The role of Chinese medicine in clinical oncology. Chin J Integr Med. 2014;20:3–10.CrossRef
9.
go back to reference He QH, Li YQ, Zhou X. Traditional Chinese medicine promotes the development of andrology. Zhonghua Nan Ke Xue. 2016;22:675–9.PubMed He QH, Li YQ, Zhou X. Traditional Chinese medicine promotes the development of andrology. Zhonghua Nan Ke Xue. 2016;22:675–9.PubMed
10.
go back to reference Liang HF, Yang YH, Chen PC, Kuo HC, Chang CH, Wang YH, Wu KM. Prescription patterns of traditional Chinese medicine amongst Taiwanese children: a population-based cohort study. BMC Complement Altern Med. 2018;18:191.CrossRef Liang HF, Yang YH, Chen PC, Kuo HC, Chang CH, Wang YH, Wu KM. Prescription patterns of traditional Chinese medicine amongst Taiwanese children: a population-based cohort study. BMC Complement Altern Med. 2018;18:191.CrossRef
11.
go back to reference DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. J Clin Oncol. 2002;20(18suppl):34S–8S.PubMed DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. J Clin Oncol. 2002;20(18suppl):34S–8S.PubMed
12.
go back to reference Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, Bruyns I, Fernadez-Ortega P, Panteli V, Margulies A, Gudmundsdottir G, Milovics L, Ozden G, Platin N, Patiraki E. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer. 2006;14:260–7.CrossRef Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, Bruyns I, Fernadez-Ortega P, Panteli V, Margulies A, Gudmundsdottir G, Milovics L, Ozden G, Platin N, Patiraki E. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer. 2006;14:260–7.CrossRef
13.
go back to reference Huebner J, Muenstedt K, Prott FJ, Stoll C, Micke O, Buentzel J, Muecke R, Senf B. Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care. 2014;9:60–3.CrossRef Huebner J, Muenstedt K, Prott FJ, Stoll C, Micke O, Buentzel J, Muecke R, Senf B. Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care. 2014;9:60–3.CrossRef
14.
go back to reference Sun X, Zhang X, Nian JY, Guo J, Yin Y, Zhang GL, Yu MW, Zhang Y, Wang XM, Yang GW, Yang L, Cheng PY, Li JP. Chinese herbal medicine as adjunctive therapy to chemotherapy for breast cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2016;2016:3281968.PubMedPubMedCentral Sun X, Zhang X, Nian JY, Guo J, Yin Y, Zhang GL, Yu MW, Zhang Y, Wang XM, Yang GW, Yang L, Cheng PY, Li JP. Chinese herbal medicine as adjunctive therapy to chemotherapy for breast cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2016;2016:3281968.PubMedPubMedCentral
15.
go back to reference Harris P, Rees R. The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature. Complement Ther Med. 2000;8:88–96.CrossRef Harris P, Rees R. The prevalence of complementary and alternative medicine use among the general population: a systematic review of the literature. Complement Ther Med. 2000;8:88–96.CrossRef
16.
go back to reference Ernst E. Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ. 2000;78:252–7.PubMedPubMedCentral Ernst E. Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ. 2000;78:252–7.PubMedPubMedCentral
17.
go back to reference Cui Y, Shu XO, Gao YT, Wen WQ, Ruan ZX, Jin F, Zheng W. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat. 2004;85:263–70.CrossRef Cui Y, Shu XO, Gao YT, Wen WQ, Ruan ZX, Jin F, Zheng W. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat. 2004;85:263–70.CrossRef
18.
go back to reference Adams M, Jewell AP. The use of complementary and alternative medicine by cancer patients. Int Semin Surg Oncol. 2007;4:10.CrossRef Adams M, Jewell AP. The use of complementary and alternative medicine by cancer patients. Int Semin Surg Oncol. 2007;4:10.CrossRef
19.
go back to reference Boon HS, Olatunde F, Zick SM. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health. 2007;7:4.CrossRef Boon HS, Olatunde F, Zick SM. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health. 2007;7:4.CrossRef
20.
go back to reference Cooke M, Mitchell M, Tiralongo E, Murfield J. Complementary and alternative medicine and critical care nurses: a survey of knowledge and practices in Australia. Aust Crit Care. 2012;25:213–23.CrossRef Cooke M, Mitchell M, Tiralongo E, Murfield J. Complementary and alternative medicine and critical care nurses: a survey of knowledge and practices in Australia. Aust Crit Care. 2012;25:213–23.CrossRef
21.
go back to reference Yeh YC, Chen HY, Yang SH, Lin YH, Chiu JH, Lin YH, Chen JL. Hedyotis diffusa combined with Scutellaria barbata are the core treatment of Chinese herbal medicine used for breast cancer patients: a population-based study. Evid Based Complement Alternat Med. 2014;2014:202378.PubMedPubMedCentral Yeh YC, Chen HY, Yang SH, Lin YH, Chiu JH, Lin YH, Chen JL. Hedyotis diffusa combined with Scutellaria barbata are the core treatment of Chinese herbal medicine used for breast cancer patients: a population-based study. Evid Based Complement Alternat Med. 2014;2014:202378.PubMedPubMedCentral
22.
go back to reference Zhou R, Chen H, Chen J, Chen X, Wen Y, Xu L. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Altern Med. 2018;18:83.CrossRef Zhou R, Chen H, Chen J, Chen X, Wen Y, Xu L. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Altern Med. 2018;18:83.CrossRef
23.
go back to reference Steven C. Fluid Physiology and Pathology in Traditional Chinese Medicine. Churchill Livingstone; 1995. p. 154. Steven C. Fluid Physiology and Pathology in Traditional Chinese Medicine. Churchill Livingstone; 1995. p. 154.
24.
go back to reference Philippe S, Lu G. The treatment of disease in TCM: general symptoms, vol. 7; 2000. p. 16. Philippe S, Lu G. The treatment of disease in TCM: general symptoms, vol. 7; 2000. p. 16.
25.
go back to reference Li P, Zhang ZM, Li T, Zhang YB, Sze SC, Wang GC, Li YL, Ye WC. Monoterpene derivatives from the roots of Paeonia lactiflora and their anti-proliferative activity. Fitoterapia. 2014;98:124–9.CrossRef Li P, Zhang ZM, Li T, Zhang YB, Sze SC, Wang GC, Li YL, Ye WC. Monoterpene derivatives from the roots of Paeonia lactiflora and their anti-proliferative activity. Fitoterapia. 2014;98:124–9.CrossRef
26.
go back to reference Wang YL, Tan X, Yang XL, Li XY, Bian K, Zhang DD. Total flavonoid from Glycyrrhizae Radix et Rhizoma and its ingredient isoliquiritigenin regulation M2 phenotype polarization of macrophages. Zhongguo Zhong Yao Za Zhi. 2015;40(22):4475–81.PubMed Wang YL, Tan X, Yang XL, Li XY, Bian K, Zhang DD. Total flavonoid from Glycyrrhizae Radix et Rhizoma and its ingredient isoliquiritigenin regulation M2 phenotype polarization of macrophages. Zhongguo Zhong Yao Za Zhi. 2015;40(22):4475–81.PubMed
27.
go back to reference Yu FR, Lian XZ, Guo HY, McGuire PM, Li RD, Wang R, Yu FH. Isolation and characterization of methyl esters and derivatives from Euphorbia kansui (Euphorbiaceae) and their inhibitory effects on the human SGC-7901 cells. J Pharm Pharm Sci. 2005;8:528–35.PubMed Yu FR, Lian XZ, Guo HY, McGuire PM, Li RD, Wang R, Yu FH. Isolation and characterization of methyl esters and derivatives from Euphorbia kansui (Euphorbiaceae) and their inhibitory effects on the human SGC-7901 cells. J Pharm Pharm Sci. 2005;8:528–35.PubMed
28.
go back to reference Su T, Zhang WW, Zhang YM, Cheng BC, Fu XQ, Li T, Guo H, Li YX, Zhu PL, Cao H, Yu ZL. Standardization of the manufacturing procedure for Pinelliae Rhizoma Praeparatum cum Zingibere et Alumine. J Ethnopharmacol. 2016;193:663–9.CrossRef Su T, Zhang WW, Zhang YM, Cheng BC, Fu XQ, Li T, Guo H, Li YX, Zhu PL, Cao H, Yu ZL. Standardization of the manufacturing procedure for Pinelliae Rhizoma Praeparatum cum Zingibere et Alumine. J Ethnopharmacol. 2016;193:663–9.CrossRef
29.
go back to reference Rose NR, McDonough MA, King ON, Kawamura A, Schofield CJ. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev. 2011;40(8):4364–97.CrossRef Rose NR, McDonough MA, King ON, Kawamura A, Schofield CJ. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev. 2011;40(8):4364–97.CrossRef
30.
go back to reference Al-Qahtani K, Jabeen B, Sekirnik R, Riaz N, Claridge TDW, Schofield CJ, McCullagh JSO. The broad spectrum 2-oxoglutarate oxygenase inhibitor N-oxalylglycine is present in rhubarb and spinach leaves. Phytochemistry. 2015;117:456–61.CrossRef Al-Qahtani K, Jabeen B, Sekirnik R, Riaz N, Claridge TDW, Schofield CJ, McCullagh JSO. The broad spectrum 2-oxoglutarate oxygenase inhibitor N-oxalylglycine is present in rhubarb and spinach leaves. Phytochemistry. 2015;117:456–61.CrossRef
31.
go back to reference Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, Li L, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Liu S, Xie Y, Gadde S, Li X, Wang L. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death Dis. 2018;9:815.CrossRef Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, Li L, Addison C, Dimitroulakos J, Arnaout A, Nessim C, Yao Z, Ji G, Song H, Liu S, Xie Y, Gadde S, Li X, Wang L. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death Dis. 2018;9:815.CrossRef
32.
go back to reference Chen VC, Hsieh YH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. J Cell Mol Med. 2018;22:1167–78.PubMed Chen VC, Hsieh YH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. J Cell Mol Med. 2018;22:1167–78.PubMed
33.
go back to reference Li J, Liu X, Chen H, Sun Z, Chen H, Wang L, Sun X, Li X. Multi-targeting chemoprevention of Chinese herb formula Yanghe Huayan decoction on experimentally induced mammary tumorigenesis. BMC Complement Altern Med. 2019;19:48.CrossRef Li J, Liu X, Chen H, Sun Z, Chen H, Wang L, Sun X, Li X. Multi-targeting chemoprevention of Chinese herb formula Yanghe Huayan decoction on experimentally induced mammary tumorigenesis. BMC Complement Altern Med. 2019;19:48.CrossRef
34.
go back to reference Liu J, Wang S, Zhang Y, Fan HT, Lin HS. Traditional Chinese medicine and cancer: history, present situation, and development. Thorac Cancer. 2015;6:561–9.CrossRef Liu J, Wang S, Zhang Y, Fan HT, Lin HS. Traditional Chinese medicine and cancer: history, present situation, and development. Thorac Cancer. 2015;6:561–9.CrossRef
35.
go back to reference Shen J, Kai J, Tang Y, Zhang L, Su S, Duan JA. The chemical and biological properties of Euphorbia kansui. Am J Chin Med. 2016;44:253–73.CrossRef Shen J, Kai J, Tang Y, Zhang L, Su S, Duan JA. The chemical and biological properties of Euphorbia kansui. Am J Chin Med. 2016;44:253–73.CrossRef
36.
go back to reference Zheng WF, Cui Z, Zhu Q. Cytotoxicity and antiviral activity of the compounds from Euphorbia kansui. Planta Med. 1998;64:754–6.CrossRef Zheng WF, Cui Z, Zhu Q. Cytotoxicity and antiviral activity of the compounds from Euphorbia kansui. Planta Med. 1998;64:754–6.CrossRef
37.
go back to reference Cheng F, Yang Y, Zhang L, Cao Y, Yao W, Tang Y, Ding A. A natural triterpene derivative from Euphorbia kansui inhibits cell proliferation and induces apoptosis against rat intestinal epithelioid cell line in vitro. Int J Mol Sci. 2015;16:18956–75.CrossRef Cheng F, Yang Y, Zhang L, Cao Y, Yao W, Tang Y, Ding A. A natural triterpene derivative from Euphorbia kansui inhibits cell proliferation and induces apoptosis against rat intestinal epithelioid cell line in vitro. Int J Mol Sci. 2015;16:18956–75.CrossRef
38.
go back to reference Hu B, Zhang H, Meng X, Wang F, Wang P. Aloe-emodin from rhubarb (Rheum rhabarbarum) inhibits lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. J Ethnopharmacol. 2014;153:846–53.CrossRef Hu B, Zhang H, Meng X, Wang F, Wang P. Aloe-emodin from rhubarb (Rheum rhabarbarum) inhibits lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. J Ethnopharmacol. 2014;153:846–53.CrossRef
39.
go back to reference Hu H, Zhu Q, Su J, Wu Y, Zhu Y, Wang Y, Fang H, Pang M, Li B, Chen S, Lv G. Effects of an enriched extract of Paeoniflorin, a monoterpene glycoside used in Chinese herbal medicine, on cholesterol metabolism in a Hyperlipidemic rat model. Med Sci Monit. 2017;23:3412–27.CrossRef Hu H, Zhu Q, Su J, Wu Y, Zhu Y, Wang Y, Fang H, Pang M, Li B, Chen S, Lv G. Effects of an enriched extract of Paeoniflorin, a monoterpene glycoside used in Chinese herbal medicine, on cholesterol metabolism in a Hyperlipidemic rat model. Med Sci Monit. 2017;23:3412–27.CrossRef
40.
go back to reference Sun X, Li S, Xu L, Wang H, Ma Z, Fu Q, Qu R, Ma S. Paeoniflorin ameliorates cognitive dysfunction via regulating SOCS2/IRS-1 pathway in diabetic rats. Physiol Behav. 2017;174:162–9.CrossRef Sun X, Li S, Xu L, Wang H, Ma Z, Fu Q, Qu R, Ma S. Paeoniflorin ameliorates cognitive dysfunction via regulating SOCS2/IRS-1 pathway in diabetic rats. Physiol Behav. 2017;174:162–9.CrossRef
41.
go back to reference Wu JJ, Sun WY, Hu SS, Zhang S, Wei W. A standardized extract from Paeonia lactiflora and Astragalus membranaceus induces apoptosis and inhibits the proliferation, migration and invasion of human hepatoma cell lines. Int J Oncol. 2013;43:1643–51.CrossRef Wu JJ, Sun WY, Hu SS, Zhang S, Wei W. A standardized extract from Paeonia lactiflora and Astragalus membranaceus induces apoptosis and inhibits the proliferation, migration and invasion of human hepatoma cell lines. Int J Oncol. 2013;43:1643–51.CrossRef
42.
go back to reference Wu Q, Chen GL, Li YJ, Chen Y, Lin FZ. Paeoniflorin inhibits macrophage- mediated lung cancer metastasis. Chin J Nat Med. 2015;13:925–32.PubMed Wu Q, Chen GL, Li YJ, Chen Y, Lin FZ. Paeoniflorin inhibits macrophage- mediated lung cancer metastasis. Chin J Nat Med. 2015;13:925–32.PubMed
43.
go back to reference Li Y, Gong L, Qi R, Sun Q, Xia X, He H, Ren J, Zhu O, Zhuo D. Paeoniflorin suppresses pancreatic cancer cell growth by upregulating HTRA3 expression. Drug Des Devel Ther. 2017;11:2481–91.CrossRef Li Y, Gong L, Qi R, Sun Q, Xia X, He H, Ren J, Zhu O, Zhuo D. Paeoniflorin suppresses pancreatic cancer cell growth by upregulating HTRA3 expression. Drug Des Devel Ther. 2017;11:2481–91.CrossRef
44.
go back to reference Zhang ZH, Xie DD, Xu S, Xia MZ, Zhang ZQ, Geng H, Chen L, Wang DM, Wei W, Yu DX, Xu DX. Total glucosides of paeony inhibits lipopolysaccharide- induced proliferation, migration and invasion in androgen insensitive prostate cancer cells. PLoS One. 2017;12:e0182584.CrossRef Zhang ZH, Xie DD, Xu S, Xia MZ, Zhang ZQ, Geng H, Chen L, Wang DM, Wei W, Yu DX, Xu DX. Total glucosides of paeony inhibits lipopolysaccharide- induced proliferation, migration and invasion in androgen insensitive prostate cancer cells. PLoS One. 2017;12:e0182584.CrossRef
45.
go back to reference Lv C, Shi C, Li L, Wen X, Xian CJ. Chinese herbal medicines in the prevention and treatment of chemotherapy-induced nausea and vomiting. Curr Opin Support Palliat Care. 2018;12:174–80.PubMed Lv C, Shi C, Li L, Wen X, Xian CJ. Chinese herbal medicines in the prevention and treatment of chemotherapy-induced nausea and vomiting. Curr Opin Support Palliat Care. 2018;12:174–80.PubMed
46.
go back to reference Levy JM, Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther. 2011;131:130–41.CrossRef Levy JM, Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther. 2011;131:130–41.CrossRef
47.
go back to reference Maycotte P, Thorburn A. Autophagy and cancer therapy. Cancer Biol Ther. 2011;11:127–37.CrossRef Maycotte P, Thorburn A. Autophagy and cancer therapy. Cancer Biol Ther. 2011;11:127–37.CrossRef
48.
go back to reference Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med. 2014;65:139–55.CrossRef Bai L, Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu Rev Med. 2014;65:139–55.CrossRef
49.
go back to reference Fulda S. Targeting autophagy for the treatment of cancer. Biol Chem. 2018;399:673–7.CrossRef Fulda S. Targeting autophagy for the treatment of cancer. Biol Chem. 2018;399:673–7.CrossRef
50.
go back to reference Kallunki T, Olsen OD, Jaattela M. Cancer-associated lysosomal changes: friends or foes? Oncogene. 2013;32:1995–2004.CrossRef Kallunki T, Olsen OD, Jaattela M. Cancer-associated lysosomal changes: friends or foes? Oncogene. 2013;32:1995–2004.CrossRef
51.
go back to reference Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.CrossRef Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.CrossRef
52.
go back to reference Abdullah LN, Chow EKH. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013;2:3.CrossRef Abdullah LN, Chow EKH. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013;2:3.CrossRef
53.
go back to reference Jia D, Li L, Andrew S, Allan D, Li X, Lee J, Ji G, Yao Z, Gadde S, Figeys D, Wang L. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death Dis. 2017;8:e2932.CrossRef Jia D, Li L, Andrew S, Allan D, Li X, Lee J, Ji G, Yao Z, Gadde S, Figeys D, Wang L. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death Dis. 2017;8:e2932.CrossRef
54.
go back to reference Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lonborg A, Vindeløv SD, Hanahan D, Arenz C, Ejsing CS, Kirkegaard T, Rohde M, Nylandsted J, Jäättelä M. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013;24:379–93.CrossRef Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lonborg A, Vindeløv SD, Hanahan D, Arenz C, Ejsing CS, Kirkegaard T, Rohde M, Nylandsted J, Jäättelä M. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 2013;24:379–93.CrossRef
55.
go back to reference Ross DT, Perou CM. A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers. 2001;17:99–109.CrossRef Ross DT, Perou CM. A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers. 2001;17:99–109.CrossRef
56.
go back to reference Furth PA. STAT signaling in different breast cancer sub-types. Mol Cell Endocrinol. 2014;382:612–5.CrossRef Furth PA. STAT signaling in different breast cancer sub-types. Mol Cell Endocrinol. 2014;382:612–5.CrossRef
57.
go back to reference Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother. 2015;16:983–98.CrossRef Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother. 2015;16:983–98.CrossRef
58.
go back to reference Williams MM, Lee L, Werfel T, Joly MMM, Hicks DJ, Rahman B, Elion D, McKernan C, Sanchez V, Estrada MV, Massarweh S, Elledge R, Duvall C, Cook RS. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis. 2018;9:21.CrossRef Williams MM, Lee L, Werfel T, Joly MMM, Hicks DJ, Rahman B, Elion D, McKernan C, Sanchez V, Estrada MV, Massarweh S, Elledge R, Duvall C, Cook RS. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis. 2018;9:21.CrossRef
59.
go back to reference Riobo-Del Galdo NA, Lara Montero Á, Wertheimer EV. Role of hedgehog signaling in breast cancer: pathogenesis and therapeutics. Cells. 2019;8:E375.CrossRef Riobo-Del Galdo NA, Lara Montero Á, Wertheimer EV. Role of hedgehog signaling in breast cancer: pathogenesis and therapeutics. Cells. 2019;8:E375.CrossRef
60.
go back to reference Cao W, Li J, Hao Q, Vadgama JV, Wu Y. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019;21:29.CrossRef Cao W, Li J, Hao Q, Vadgama JV, Wu Y. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Breast Cancer Res. 2019;21:29.CrossRef
61.
go back to reference Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50:33.CrossRef Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50:33.CrossRef
62.
go back to reference Zhou X, Seto SW, Chang D, Kiat H, Razmovski-Naumovski V, Chan K, Bensoussan A. Synergistic effects of Chinese herbal medicine: a comprehensive review of methodology and current research. Front Pharmacol. 2016;7:201.PubMedPubMedCentral Zhou X, Seto SW, Chang D, Kiat H, Razmovski-Naumovski V, Chan K, Bensoussan A. Synergistic effects of Chinese herbal medicine: a comprehensive review of methodology and current research. Front Pharmacol. 2016;7:201.PubMedPubMedCentral
Metadata
Title
In vitro and in vivo effects of traditional Chinese medicine formula T33 in human breast cancer cells
Authors
Yu-Te Liu
Chao-Hsiang Hsiao
Bor-Show Tzang
Tsai-Ching Hsu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2019
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-019-2630-5

Other articles of this Issue 1/2019

BMC Complementary Medicine and Therapies 1/2019 Go to the issue